1College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Henan, Xinyang-464 000, P.R. China.
*Corresponding Author: Yapei Rui, College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Henan, Xinyang-464 000, P.R. China. Email: 2008200001@xyafu.edu.cn
There are currently no clinical breakpoints available to facilitate data interpretation and the correlation of MICs with in vivo efficacy. Defining the break point of enrofloxacin for Mycoplasma hyopneumoniae can determine the choice of empirical treatment and targeted therapy, predict the efficacy of drugs against specific animals and analyze treatment failure.
We determined the breakpoint of M. hyopneumonaie to enrofloxacin by susceptibility testing and pharmacokinetics/ pharmacodynamics model.
The pharmacodynamic cutoff value of M. hyopneumoniae against enrofloxacin was 0.25 μg/mL and the clinical break point was 2 μg/mL. After comprehensive weighing, the final sensitivity break point was set at 2 μg/mL. To provide reference for in vitro bacteriostatic test of M. hyopneumonaie against enrofloxacin. To provide the basis for the actual dosage of enrofloxacin in the treatment of mycoplasma pneumonia in pigs.
Break point, Enrofloxacin, MIC, Mycoplasma hyopneumoniae, Pharmacodynamics
